Hetero
Chinni Krishnareddy Gangireddy has extensive experience in the pharmaceutical industry. CHINNI is currently serving as the Vice President of Manufacturing at Hetero since November 2022. Prior to that, they worked at Therapiva Pvt. Ltd as the Chief Operating Officer and Operations Head from July 2021 to October 2022. Before that, they held the position of Head of site operations at Mylan from September 2017 to May 2021. CHINNI also served as AVP, Head of API Site at Macleods limited from January 2013 to September 2017. Chinni Krishnareddy Gangireddy has a strong background in manufacturing and operations, having previously worked as Head Manufacturing at Hetero Drugs Ltd from October 2009 to December 2012. CHINNI started their career at Dr. Reddy's Laboratories as a Manager from June 1995 to September 2009 and began their professional journey at BENZEX LABS LTD as a Sr.Executive from June 1989 to May 1995.
CHINNI KRISHNAREDDY GANGIREDDY's education history includes completing a Bachelor's Degree in General Studies at Degree Colleage Anantapur from 1985 to 1988. Later, from 2001 to 2004, they pursued a Master's Degree in Pharmaceutical chemistry at Birla Institute of Technology & Science, Pilani. Finally, from 2004 to 2006, CHINNI KRISHNAREDDY GANGIREDDY earned a Master of Business Administration (M.B.A.) degree with a concentration in Marketing and Operation Systems from Sikkim Manipal University - Distance Education.
This person is not in the org chart
This person is not in any offices
Hetero
4 followers
Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs. Backed by 25 years of expertise in the pharmaceutical industry, Hetero’s strategic business areas spread across APIs, generics, biosimilars, custom pharmaceutical services and branded generics. The company is globally recognized for its strengths in Research and Development, manufacturing and commercialization of a wide range of products. Hetero has 36 state-of-the-art manufacturing facilities strategically located worldwide, approved by stringent global regulatory authorities. Our portfolio includes 300 plus products encompassing major therapeutic categories such as HIV/AIDS, Oncology, Cardiovascular, Neurology, Hepatitis, Nephrology, Urology, Diabetes, Ophthalmology, Hepatology and Immunology etc. Hetero has a strong global presence in over 145+ countries and focusses on making affordable medicines accessible to patients worldwide.